Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-Based Technology
CytoMed Therapeutics Limited, a Singapore-based biopharmaceutical company, has announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA). This patent strengthens CytoMed’s existing suite of patents and expands its current patent portfolio to three countries, including the US and China.
The iPSC-based technology allows CytoMed to generate a novel type of synthetic hybrid immune cells called γδ NKT cells. These cells express cancer recognition receptors of both γδ T cells and natural killer (NK) cells, enabling them to recognize a wide range of cancers without genetic modification or the use of viral vectors. As an allogeneic cell source, the iPSC-derived γδ NKT cells have the potential to become an “off-the-shelf” cell therapy applicable to a large pool of patients.
The patent, titled “Methods and Kits for Generating Mimetic Innate Immune Cells from Pluripotent Stem Cells,” covers technologies to derive novel synthetic γδ NKT cells for the treatment of various types of cancers, including hematological malignancies and solid tumors. This asset is currently under preclinical development.
CytoMed Therapeutics is focused on harnessing its licensed proprietary technologies to develop novel cell-based immunotherapies for the treatment of human cancers. The company was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency, in 2018.
For more information, please visit www.cytomed.sg.
